Schwab Charles Investment Management Inc. Raises Holdings in Atrion Co. (ATRI)

Schwab Charles Investment Management Inc. grew its stake in Atrion Co. (NASDAQ:ATRI) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,972 shares of the medical instruments supplier’s stock after purchasing an additional 115 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Atrion were worth $4,397,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ATRI. Neuberger Berman Group LLC raised its holdings in Atrion by 4.0% in the 3rd quarter. Neuberger Berman Group LLC now owns 86,185 shares of the medical instruments supplier’s stock worth $57,916,000 after purchasing an additional 3,291 shares in the last quarter. First Trust Advisors LP bought a new position in Atrion in the 3rd quarter worth $1,740,000. JPMorgan Chase & Co. raised its holdings in Atrion by 145.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,057 shares of the medical instruments supplier’s stock worth $2,732,000 after purchasing an additional 2,402 shares in the last quarter. American Century Companies Inc. bought a new position in Atrion in the 3rd quarter worth $1,094,000. Finally, Dimensional Fund Advisors LP raised its holdings in Atrion by 1.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 64,290 shares of the medical instruments supplier’s stock worth $43,203,000 after purchasing an additional 1,022 shares in the last quarter. Institutional investors and hedge funds own 59.17% of the company’s stock.

How to Become a New Pot Stock Millionaire

Atrion Co. (NASDAQ ATRI) opened at $606.50 on Friday. The company has a market cap of $1,124.48, a price-to-earnings ratio of 32.85 and a beta of 0.70. Atrion Co. has a 1-year low of $459.50 and a 1-year high of $694.00.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $4.66 earnings per share (EPS) for the quarter. The company had revenue of $34.02 million during the quarter. Atrion had a net margin of 24.96% and a return on equity of 19.53%.

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Thursday, March 15th will be paid a $1.20 dividend. The ex-dividend date is Wednesday, March 14th. This represents a $4.80 annualized dividend and a dividend yield of 0.79%. Atrion’s payout ratio is 24.35%.

Separately, BidaskClub lowered shares of Atrion from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 9th.

ILLEGAL ACTIVITY WARNING: This report was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.chaffeybreeze.com/2018/03/17/schwab-charles-investment-management-inc-raises-holdings-in-atrion-co-atri.html.

Atrion Company Profile

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Want to see what other hedge funds are holding ATRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atrion Co. (NASDAQ:ATRI).

Institutional Ownership by Quarter for Atrion (NASDAQ:ATRI)

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply